Canada Markets closed

Amyris, Inc. (AMRS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.8600-0.1750 (-4.34%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close4.0350
Open4.0500
Bid3.8500 x 3200
Ask3.8700 x 1300
Day's Range3.5800 - 4.0800
52 Week Range1.4000 - 6.0700
Volume4,163,243
Avg. Volume2,822,835
Market Cap789.825M
Beta (5Y Monthly)0.52
PE Ratio (TTM)N/A
EPS (TTM)-2.2690
Earnings DateNov. 05, 2020 - Nov. 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
  • GlobeNewswire

    Rigrodsky & Long, P.A. Files Class Action Suit Against Amyris, Inc.

    WILMINGTON, Del., July 29, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court for the District of Delaware on behalf of holders of Amyris, Inc. (“Amyris” or the “Company”) (NASDAQ GS: AMRS) common stock (the “Complaint”).  The Complaint, which alleges violations of the Securities Exchange Act of 1934 against Amyris and its Board of Directors (the “Board”), is captioned Sabatini v. Amyris, Inc., Case No. 1:20-cv-01013 (D. Del.). If you wish to discuss this action or have any questions regarding this notice or your rights, please contact plaintiff’s counsel, Seth D. Rigrodsky or Gina M. Serra, toll free at (888) 969-4242, by e-mail at info@rl-legal.com, or at https://www.rigrodskylong.com/offices-contact.On July 6, 2020, Amyris filed a proxy statement (the “Proxy Statement”) with the United States Securities and Exchange Commission.  The Proxy Statement scheduled a special meeting of Amyris’ stockholders to vote upon the approval of:  (i) the issuance of shares of Amyris’ common stock issuable upon exercise by Foris Ventures, LLC of its option to convert all or any portion of the secured indebtedness outstanding under the Amended and Restated Loan and Security Agreement dated October 28, 2019, as further amended on June 1, 2020, into shares of the Company’s common stock; and (ii) the issuance of shares of Amyris common stock issuable upon the conversion of the Company’s Series E Convertible Preferred Stock.  Among other things, the Complaint alleges that defendants issued materially incomplete disclosures in the Proxy Statement. If you wish to serve as lead plaintiff, you must move the Court no later than September 28, 2020.  A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.  Any member of the proposed class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.Attorney advertising.  Prior results do not guarantee a similar outcome.CONTACT:Rigrodsky & Long, P.A. Seth D. Rigrodsky Gina M. Serra (888) 969-4242 (Toll Free) (302) 295-5310 Fax: (302) 654-7530 info@rl-legal.com https://rl-legal.com

  • Here's Why Amyris Stock Rose as Much as 12.2% Today
    Motley Fool

    Here's Why Amyris Stock Rose as Much as 12.2% Today

    Shares of Amyris (NASDAQ: AMRS) gained over 12% today after the company announced it had signed a binding term sheet with the Infectious Disease Research Institute (IDRI) to collaborate on a SARS-CoV-2 vaccine candidate. Specifically, IDRI will develop a vaccine candidate based on its RNA vaccine platform, while Amyris will supply squalene for use in the vaccine adjuvant.